Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis

Anti-Cancer Drugs

Volumn 15, Issue 4, 2004, Pages 405-409

  Ramadori, Giuliano ^a,d   Füzesi, Laszlo ^b   Grabbe, Eckhardt ^c   Pieler, Tomas ^d   Armbrust, Thomas ^a  

^a Center of Internal Medicine   (Germany)

^b Department of Gastroenteropathology ^*

^c Center of Radiology   (Serbia)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Hepatocellular carcinoma; Imatinib; Liver cirrhosis; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB;

AGED; ANAMNESIS; ARTICLE; CANCER THERAPY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; MALE; MEDICAL EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 1942485318     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200404000-00014     Document Type: Article

References (23)

1. Kew MC. Epidemiology of hepatocellular carcinoma. Toxicology 2002; 181-182:35-38.
2. El-Serag HB. Epidemiology of hepatocellular carcinoma. In: Holland K (editor): Clinics in Liver Disease. Philadelphia, PA: Saunders; 2001; 5, pp. 87-107.
3. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33:62-65.
4. Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35:S130-S137.
5. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1997; 27:756-765.
6. Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129:643-653.
7. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002; 35:S109-S114.
8. Pitot HC. Pathways of progression in hepatocarcinogenesis. Lancet 2001; 358:859-860.
9. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336:1150-1153.
10. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002; 62(suppl 1):29-37.
11. Thorgeirsson SS, Evarts RP, Bisgaard HC, Fujio K, Hu Z. Hepatic stem cell compartment: activation and lineage commitment. Proc Soc Exp Biol Med 1993; 204:253-260.
12. Thorgeirsson SS. Progenitor cell tumors in human liver. Liver 1998; 18:227-228.
13. Fujio K, Hu Z, Evarts RP, Marsden ER, Niu CH, Thorgeirsson SS. Coexpression of stem cell factor and c-kit in embryonic and adult liver. Exp Cell Res 1996; 224:243-250.
14. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31:1037-1051.
15. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001; 25:571-576.
16. DeSilva CM, Reid R. Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003; 9:13-19.
17. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
18. 8 Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108:812-817.
19. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-680.
20. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21:1029-1034.
21. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res 1989; 49:1554-1561.
22. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-797.
23. Potti A, Ganti AK, Tendulkar K, Chitajallu S, Sholes K, Koch M, et al. HER-2/neu and CD117 (c-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003; 23:2671-2674.